Insulin oral - Generex Biotechnology

Drug Profile

Insulin oral - Generex Biotechnology

Alternative Names: Insulin buccal - Generex; Oral Recosulin; Oral-lyn; Oralgen

Latest Information Update: 23 Mar 2017

Price : $50

At a glance

  • Originator Generex Biotechnology Corporation
  • Developer Generex Biotechnology Corporation; Leosons
  • Class Antihyperglycaemics; Insulins; Pancreatic hormones
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Tyrosine aminotransferase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Type 1 diabetes mellitus; Type 2 diabetes mellitus
  • Discontinued Glucose intolerance

Most Recent Events

  • 23 Mar 2017 Discontinued - Phase-II for Glucose intolerance in Italy (Buccal) (Generex Biotechnology Corporation pipeline, March 2017)
  • 13 Jan 2017 Generex Biotechnology has patent protection for Insulin oral in USA, Canada, Monaco, Switzerland & Liechtenstein and European Union (Generex Biotechnology Corporation 10-K, January 2017)
  • 25 Aug 2015 Pharmacodynamics data from a preclinical trial in Type-II diabetes mellitus released by Generex
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top